Background. Anemia in patients with end-stage renal disease (ESRD) is treated with recombinant human erythropoietin (rhEPO) often in combination with iron. However, iron catalyzes the formation of toxic radicals, which might promote vascular damage, is a nutrient for microorganisms, and negatively affects immune pathways, thus increasing the risk for severe infections.
Anemia is a frequent clinical condition in patients with end-stage renal disease (ESRD) and may be primarily referred to as a hypoproliferative response of erythroid progenitor cells as a result of accumulation of toxic substances in the bone marrow, an impaired production of erythropoietin (EPO), and last, but not least, to a decreased availability of iron [1, 2] , which is due to disturbances of iron homeostasis similar to that observed in chronic inflammatory disorders [3, 4] . The pathophysiology of this diversion of iron metabolism has not been fully elucidated so far but regulatory effects of cytokines on iron homeostasis appear to be of pivotal importance.
Anemia in ESRD is treated by subcutaneus or intravenous application of recombinant human erythropoietin (rhEPO) [5] . However, due to limited availability of iron the response rates to rhEPO are sometimes not satisfactory and thus iron has to be administered in parallel mostly intravenously to gain a sufficient increase in hemoglobin levels [6] [7] [8] . However, iron therapy may induce effects other than anemia correction, which may be associated with an unfavorable clinical course in ESRD patients. First, iron influences the immune balance by down-regulating the effectivity of the central T-helper cell type-1 (Th-1) cytokine interferon-gamma (IFN-␥) toward human monocytes/macrophages. This leads to impaired formation of nitric oxide, tumor necrosis factor-␣ (TNF-␣) or surface expression of major histocompatibility (MHC) class II antigens by macrophages, thereby weakening cell-mediated immune response toward invading pathogens [9, 10] . Additionally, administration of iron increases the availability of this essential nutrient for microorganisms and has thus been found to be associated with an increased incidence of infectious complications in ESRD patients [11, 12] .
On the other hand, iron catalyses the formation of highly toxic hydroxyl radicals by the Haber-Weiss reaction [13] . Oxygen radical formation and subsequent lipid peroxidation are postulated to be involved in the pathogenesis of atherosclerosis [14] . Several epidemiologic studies have investigated the role of iron as a potential risk factor for coronary heart disease. Elevated body iron stores were associated with an increased risk of coronary heart disease-related death or myocardial infarction in some [15, 16] , but not in all studies [17, 18] . Moreover, although patients with ESRD appear to be immunocompromised, increased levels of proinflammatory cytokines such as TNF-␣, [19] , IL-1, and IL-6, which may be referred to the dialysis procedure, have been observed. [20] . Thus, TNF-␣ may contribute to tissue damage in ESRD patients in being a potent inducer of radical formation by cells of the reticuloendothelial system [13] .
Since no clinical data were available so far on the effects of iron substitution on immune function and endogenous oxidative stress in ESRD patients, the study presented herein was initiated.
METHODS

Patients
We investigated a total of 31 patients with ESRD who underwent regular hemodialysis therapy. All subjects were on chronic hemodialysis for at least 6 months, received 50 to 150 IU rhEPO/kg bodyweight per week, had serum ferritin levels between 200 and 500 g/L, and hemoglobin values between 11.5 g/dL and 12.5 g/dL before entering the study. Patients with signs of acute infections or inflammation, major comorbid conditions such as malignancies, recurrent gastrointestinal bleeding, and clinical signs or symptoms of coronary heart disease were excluded. The study was approved by the local ethical committee and written informed consent was obtained from all patients. Prior to study entry, all patients received rhEPO three times a week (Neorecormon; Roche, Mannheim, Germany) and, in addition, iron saccharate according to serum ferritin levels intravenously. One week prior to study entry, iron was withdrawn. Patients were then randomly assigned to receive either rhEPO and iron (100 mg/week) or rhEPO alone. Patients were then followed for 3 months and blood samples for investigation of cytokines and oxidative stress were drawn at day 0 (study entry), day 7, day 14, day 28, and day 90 (end of study). None of the patients received a blood transfusion over the study period. Three patients did not complete the study. In one case, the patient retracted the informed consent and two others underwent renal transplantation.
All patients were dialyzed three times a week for 3 to 5 hours with either a Hemophan dialyser (HG 600, Gambro, Vienna, Austria) (N ϭ 16) or a Polysulfon dialyzer (F60 or F8, Fresenius, Graz, Austria) (N ϭ 12) using bicarbonate dialysate and a blood flow between 250 mL/min and 350 mL/min. Dialysis prescription remained unchanged during the study period. Mean Kt/V of the study group was 1.35 and mean normalized polymerase chain raction (PCR) was 1.03 with no difference between the iron/rhEPO or rhEPO group. Iron and rhEpo were administrated at the end of hemodialysis.
Laboratory determinations
Blood samples were drawn immediately before hemodialysis. Laboratory parameters [e.g., alanine aminotransferase (ALT), aspartate aminotransferase (AST), hemoglobin, blood cell count, and iron content] were examined by routinely used automated laboratory tests, ferritin concentration by an immunoassay, and transferrin concentration by a turbitometric method.
Serum specimens were drawn during this routine examination and stored in aliquots at Ϫ70ЊC until cytokine assays were performed. Determinations of serum concentrations of TNF-␣, IL-4, IL-6, IL-10, and IL-12p40 were all carried out by commercially available enzymelinked immunosorbent assay (ELISA) kits obtained from R&D (Minneapolis, MN, USA). The detection limits were 2 ng/L for TNF-␣, 5 ng/L for IL-4, 0.7 ng/L for IL-6, 2 ng/L for IL-10, and 2.5 ng/L for IL-12p40, respectively.
For determination of plasma total peroxide concentrations we used the "peroxide activity" assay from Tatzber KEG (Klosterneuburg, Austria), which is based on the reaction of horseradish peroxidase with plasma peroxides using tetramethylbenzidine as the chromogen substrate. Employing a hydrogen peroxide (H 2 O 2 ) standard curve, total peroxide concentrations were calculated and expressed as micromole H 2 O 2 equivalents per liter plasma. POX reflects total peroxide concentration in plasma or serum samples and is thus an indicator for the concentration of reactive oxygen species in plasma/serum.
Statistical analyses
Analyses were carried out using the statistical software package SYSTAT 7.01 (SPSS, Inc., Chicago, IL, USA). Continuous variables were compared according to treatment category by Student t test after Bonferroni correction for multiple testing. Since immunologic parameters followed skewed rather than Gaussian distributions, they were evaluated by nonparametric statistical analysis (Kruskal-Wallis). This procedure minimizes the possibility of biasing of results by a few outliers. Trends over time in cytokine levels, iron status parameters, POX activity, and other measures according to the experimental treatment groups were analyzed by repeated measure analysis of variance (ANOVA). The significances of associations among various measures were calculated by Spearman ranks correlation technique.
RESULTS
Among the 28 patients finishing the study 13 received additional iron therapy, while 15 received rhEPO alone. Weekly rhEPO dosages were not significantly different between the two treatment groups at study entry. The baseline characteristics of all patients are shown in Table  1 and no statistically significant differences were found among the two groups concerning baseline hematologic parameters, iron status, or cytokine levels. Nonetheless, baseline levels for TNF-␣, IL-4, and IL-6 were increased in both patient groups (Table 1 ) as compared to mean values obtained in healthy volunteers according to the manufacturer's instructions corresponding to Ͻ2 ng/L for TNF-␣, Ͻ10 ng/L of IL-4, and Ͻ5 ng/L for IL-6, respectively.
During the treatment period no significant change in hemoglobin levels over time was observed between the two treatment groups (Table 2) . Moreover, mean weekly rhEPO concentrations did not change significantly in either treatment group over the study period of 3 months (details not shown). When investigating iron status, we found a significant decrease in ferritin levels in subjects receiving rhEPO alone, while ferritin concentration progressively increased when additional iron was given (Table 2). In parallel, in the latter group, transferrin saturation significantly increased over time.
When studying the effects of iron treatment on serum cytokine levels, we found that TNF-␣ concentrations declined in patients receiving additional iron, while in subjects treated with rhEPO alone, TNF-␣ levels increased and were significantly higher than in patients receiving additional iron at the end of the observation period (Fig. 1) . In parallel to TNF-␣, serum levels of haptoglobin, another acute phase protein, and IL-6 progressively increased in patients receiving rhEPO alone (Table 2 ). In contrast, serum concentrations of the T-helper cell type-2 (Th-2)-derived cytokine IL-4 decreased in patients receiving EPO, while additional application of iron lead to a significant increase of IL-4 levels ( Table 2) .
Endogenous radical formation was estimated by measuring total peroxide activity (POX) [21] . While POX activity slightly increased over time in the rhEPO treatment group, the opposite was true in patients receiving additional iron; however, these differences were not statistically significant (Table 2) .
To achieve greater insights toward the interrelationship between iron, immune function, and oxidative stress, we calculated of Spearman rank correlation coefficients in either group at the end of treatment. When investigating patients receiving rhEPO and additional iron therapy, we found a highly significantly positive correlation between IL-4 and hemoglobin levels, while IL-4 was negatively associated with TNF-␣ concentrations. In line with this, we found TNF-␣ to be positively associated with EPO dosages used in patients, while for IL-4 just the opposite was true (Table 3) . When examining the interrelationship between iron availability as reflected by transferrin saturation and cytokines, we found a negative association between transferrin saturation and TNF-␣ and a positive one between transferrin saturation and IL-4 (Fig. 2) .
In patients receiving no additional iron treatment, TNF-␣ concentrations were negatively associated with hemoglobin levels; however, the associations between cytokines, iron homeostasis, and indicators of erythropoeisis were less pronounced as compared to patients receiving additional iron treatment.
When studying correlations between these parameters and endogenous radical formation, we found in both groups that POX was positively associated with TNF-␣ levels and negatively with transferrin saturation (Fig. 3) ; however, POX did not correlate to rhEPO dosages or hemoglobin levels in either group.
DISCUSSION
In the study presented herein, we identified profound effects of iron therapy on immune function in ESRD patients receiving rhEPO.
Currently, it is well established that there exist three CD4ϩ T-helper cell subsets in humans, termed as naive T-helper cells, Th-1, Th-2, and Th-3, each of which is producing a typical set of cytokines that regulate different immune effector functions and which crossreact with each other [22] . Th-1-derived cytokines such as IFN-␥ or tumor necrosis factor-␤ (TNF-␤) activate macrophages, thus contributing to the formation of proinflammatory 
Fig. 1. Changes in tumor necrosis factor-␣ (TNF-␣) levels in end-stage renal disease (ESRD) patients as a function of iron therapy.
ESRD patients were treated with recombinant human erythropoietin (rhEPO) for correction of renal anemia and were then randomly assigned to receive either additional iron or not over a period of 3 months. Day 1 was at study entry and day 90 was the end of study. TNF-␣ was determined in patients' sera as outlined in the Methods section. *P ϭ 0.017, difference in circulating TNF-␣ levels between the two groups at day 90 as estimated by nonparametric Kruskal-Wallis test; #P ϭ 0.006, differences in trends over time between the two treatment groups (additional iron versus none) as estimated by analysis of variance (ANOVA) analysis.
cytokines, such as TNF-␣, IL-1, or IL-6, and the induction of cytotoxic immune effector mechanisms of macrophages. By contrast, Th-2 cells produce IL-4, IL-5, IL-9, and IL-13, which, in part, exert anti-inflammatory actions via inhibition of various macrophage functions [23] .
Herein, we found that iron supplementation was associated with reduced endogenous TNF-␣ levels in patients with ESRD at study end. This may be referred to the inhibitory effect of iron toward IFN-␥ activity, which leads to impaired expression of IFN-␥-inducible genes in monocytes/macrophages, such as TNF-␣ or nitric oxide in vitro and in vivo [10, [24] [25] [26] . In a line with this, we also found that the concentrations of the anti-inflammatory Th-2-derived cytokine IL-4 levels increased with iron therapy [27] .
Nonetheless, significances in immune and iron parameters between the two groups were most pronounced at the end of the study; however, significant difference in trends (e.g., TNF-␣ levels were observed even after 4 weeks) (P ϭ 0.03). This may relate to the fact that dialysis patients are in a chronic inflammatory state and since considerable amounts of iron were present at study entry in both groups. Therefore, it appears reasonable that a prolonged period of time is needed to see iron therapymediated differences on immune function or iron homeostasis.
According to the Th-1/Th-2 paradigm [22, 23] , this observation may refer to iron-mediated impairment of IFN-␥ activity, which derepresses the inhibitory effects of this cytokine toward Th-2 cell activity, thus leading to increased formation and release of circulating IL-4 upon iron supplementation. This fits nicely to our obser- vation of a negative association between IL-4 and TNF-␣ in the iron treatment group, the contrasting correlations of transferrin saturation with IL-4 and TNF-␣, and, finally, to data obtained in infection models where iron supplementation or overload led to a shift from Th-1 to Th-2 immune function [24] [25] [26] [27] [28] . Most interestingly, in our study, iron supplementation rather decreased endogenous radical formation, as monitored by determination of POX activity. Based on the results of the Spearman rank correlations demonstrating a positive association between TNF-␣ and POX and a negative one between transferrin saturation and POX, one may speculate that iron therapy may limit peroxide formation by inhibiting the production of its main inducer, TNF-␣ [13] .
However, we can not rule out that iron may induce oxidative stress by pathways not being under the control for TNF-␣ such as lipid peroxidation, thereby causing tissue damage [29, 30] or if the lack of increased POX formation in iron-treated patients may be referred to induction of ferritin synthesis by iron therapy with subsequent incorporation and detoxification of the metal within the ferritin core protein.
Nonetheless, this leads to the questions of whether or not the effects of iron on immunity may be beneficial or detrimental to ESRD patients. On the one hand, reduced TNF-␣ activity decreases cytokine-induced oxidative stress and possibly reduces the risk of cardiac events in ESRD patients [31] . On the other hand, iron-mediated weakening of the Th-1 immune effector branch with a subsequent strengthening of Th-2-mediated immune effector function is an unfavorable condition in the case of an acute infection or tumor disease apart from the fact that increased iron availability may enhance the growth of invading pathogens and malignant tissues [12, 32] . This is especially relevant in ESRD patients since im-mune effector function in these subjects is already impaired, which has partly been referred to the antiproliferative effects of accumulating toxic substances and the continuous immune activation upon exposure of circulating blood to dialysate membranes [19, 20] . Thus, it will be mandatory to design prospective studied to get more insights toward long-lasting clinical effects of iron supplementation and subsequent immune modulation in ESRD patients.
Nonetheless, the interactions of iron with cytokines may also have important implications for the pathophysiology and therapy in renal anemia.
The positive association between IL-4 and hemoglobin levels found in patients receiving additional iron may thus result from at least two factors: (1) iron may diminished TNF-␣ formation and reduce the antiproliferative effects exerted by this cytokines toward erythroid progenitor cells [3] , an action which may be supported by increased levels of the anti-inflammatory cytokine IL-4; and (2) iron supplementation may overcome the limited availability of the metal toward erythroid progenitor cells thus stimulating erythropoiesis [7, 8] . The hypothesis that IL-4 may be beneficial in renal anemia is further supported by the finding of reduced EPO dosages needed in patients with high IL-4 levels (Table 3) , while subjects with increased circulating TNF-␣ concentrations needed more EPO for correction of anemia, which is in good accordance with previous data [33, 34] .
A limitation of our study arises from the fact that, due to ethical reasons and in order to avoid an additional biasing of the results by application of blood transfusions, our patients were only moderately anemic and iron stores were well filled up at study entry. Thus, it will be relevant to see which effects iron supplementation may have on immune regulation when patients are more anemic and/or when iron stores (as estimated by ferritin levels) and iron availability (as reflected by transferrin saturation) are reduced. Nonetheless, from this, it also is evident that continuous monitoring of iron status is an essential clinical investigation in ESRD patients being aware of the fact that the amount of circulating iron is of pivotal importance for erythropoiesis, immunosurveillance, and toxicity. For this aim, it would be beneficial to determine the amount of metabolically available iron (i.e., iron not bound to ferritin or transferrin), which may exert the biologic effects of the metal toward immunity and radical formation, in ESRD patients according to a fluorescence-based method [35] to have a better clinical monitor for iron traffic in ESRD patients.
Thus, future prospective investigations are warranted to determine the optimal concentration of iron given therapeutically to ESRD patients in order to achieve optimal results in terms of anemia correction and to minimize the detrimental effects of the metal in terms of cardiovascular toxicity and infectious complications partly linked to immunodepression.
CONCLUSION
We found that iron therapy has profound effects on immune function by inhibiting TNF-␣ production and increasing Th-2 activity via IL-4 formation. This may have important implications on the susceptibility toward infections, the risk for cardiac events, and the degree of anemia in ESRD patients.
